Prosecution Insights
Last updated: August 18, 2026
Application No. 17/944,582

DEEP TISSUE OPTICAL SENSING DEVICES AND METHODS

Final Rejection §103
Filed
Sep 14, 2022
Priority
Sep 16, 2021 — provisional 63/244,927
Examiner
LIU, CHU CHUAN
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Cardinal Health Inc.
OA Round
4 (Final)
71%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
553 granted / 776 resolved
+1.3% vs TC avg
Moderate +14% lift
Without
With
+14.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
33 currently pending
Career history
806
Total Applications
across all art units

Statute-Specific Performance

§101
10.6%
-29.4% vs TC avg
§103
37.1%
-2.9% vs TC avg
§102
14.1%
-25.9% vs TC avg
§112
26.6%
-13.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 776 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s amendments and remarks filed on 06/18/2026 have been fully considered. Claims 1-11 and 21-30 are pending for examination. Claims 12-20 are cancelled. Applicant's election with traverse of Invention I, claims 1-9, and Species B, Fig. 22, in the reply filed on 06/25/2025 are acknowledged. Claims 2 and 10-11 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions and species, there being no allowable generic or linking claim. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 3-9, 21, 24, and 26-27 are is/are rejected under 35 U.S.C. 103 as being unpatentable over Kuhn (USPGPUB 2012/0108925 – cited in previous action), in view of Shao et al. (USPGPUB 2021/0161444 – cited in previous action) and further in view of Cinbis et al. (USPGPUB 2010/0022856 – applicant cited). In regard to claim 1, Kuhn discloses an optical monitoring device (elements 12, 20, 30, 34, and/or 40, Fig. 1 and associated descriptions) comprising: a first optical emitter (one of elements 106, 106’ or 124, Figs. 2A and 2C and associated descriptions; “It is further contemplated that one light detector could be positioned to detect light emitted by two light emitters located at two different separation distances from the light detector but emitting light through a single common window. For example, vertical cavity surface emitting lasers (VCSELs) could emit light through a common window and be positioned at two different distances (one nearer and one further) from a photodiode window. When a single light detector is used in combination with two light sources to obtain measurements at two separation distances, the emitted light signals are controlled in a time or frequency multiplexed manner to allow separate light attenuation measurements to be obtained for the two separation distances”, [0043]; it is noted that one of the emitter 124, similar to element 106 or 106’, is interpreted as the first emitter and element 128 may be indicative of the location of the first emitter, Fig. 2C), wherein the first optical emitter is configured to emit light at a first wavelength (any one of the wavelengths, [0035-0036]); and a second optical emitter (the other one of elements 106, 106’ or 124, Fig. 2C and associated descriptions [0043]; it is noted that the other one of the emitter 124, similar to element 106 or 106’, is interpreted as the second emitter and element 132 may be indicative of the location of the second emitter, Fig. 2C), wherein the second optical emitter is configured to emit light at a second wavelength that is different from the first wavelength (any different one of the wavelengths, [0035-0036]); and a first optical detector (one light detector, [0043] or a detector similar to elements 108, 108’, 128, or 132, Figs. 2A and 2C and associated descriptions; it is noted that the one light detector, similar to element 108 or 108’, is interpreted as the light detector and element 124 or 122 may be indicative of the location of the first light detector, Fig. 2C); wherein the first optical emitter is spaced a first distance away from the first optical detector along a planar surface of the optical monitoring device (distance between locations 128 and 124, Fig. 2C and associated descriptions; the defined first light emitter and the first light detector (nearer location), [0043] and Fig. 2C); wherein the second optical emitter is spaced a second distance away from the first optical detector along the planar surface of the optical monitoring device (distance between locations 132 and 124, Fig. 2C and associated descriptions; the defined second light emitter and the first light detector (further location), [0043] and Fig. 2C), wherein the first distance is less than the second distance (Fig. 2C and associated descriptions; [0043]); wherein the first optical emitter is configured so that the emitted light from the first optical emitter propagates through a tissue at a first depth of at least 1 cm into the tissue as measured from a surface of the optical monitoring device (according to the dimensions of elements 12, 20, 30, 34, and/or 40, Fig. 1 and associated descriptions and their associated configurations, e.g. Fig. 2C and [0043], it is inherent that some of the emitted light would propagates through a tissue at a depth of at least 1 cm into the tissue; It is also noted that the claim does not require the emitted light from the optical emitter propagates through a tissue at a depth of at least 1 cm into the tissue to be detected by the first detector); wherein emitted light from the second optical emitter propagates through the tissue to a second depth (different separation distances, Fig. 2C and associated descriptions; [0043]), wherein the first depth is less than the second depth (inherent property of the shorter separation distance between the first emitter and the first light detector, Fig. 2C and associated descriptions; [0043]); wherein the emitted light from the first optical emitter propagates through the tissue simultaneously with the emitted light from the second optical emitter (simultaneously, [0035] and [0052]; frequency multiplexed manner, [0043]); wherein the optical monitoring device is configured to determine a physiological parameter of the tissue using incident light detected by the first optical detector (tissue hemoglobin concentration, THC, and/or tissue oxygen saturation, O2Sat, [0003]; [0018]; [0030]; [0034]; [0050]; [0054]); and wherein the optical monitoring device is configured to be implanted in a tissue of a patient (implanted elements 12, 20 or 30, Fig. 1 and associated descriptions; implanted/ implantable, [0020]; [0025-0026]; [0032]; [0048]). Kuhn does not specifically disclose the first optical detector is configured to selectively detect incident light with respect to its angle of incidence on the optical monitoring device. Shao teaches a similar reflection type optical sensor (Figs. 1-10 and associated descriptions) comprises an optical detector (elements 204/304/504, Figs. 1-5 and associated descriptions) is configured to selectively detect incident light with respect to its angle of incidence on the optical monitoring device (Figs. 4A-4F and 5A-5B and associated descriptions). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the device (Kuhn) to incorporate the optical layers, optical films, lenses, and/or window systems and associated optical elements/ functions/ configurations as taught by Shao to the optical detector, since both devices are reflection type optical sensing systems and one of ordinary skill in the art would have recognized that the light restriction designs selectively allow light having an angle of incidence within one or more acceptance viewing angles and block light with angles of incidence outside of the acceptance viewing angles and reduce unwanted/ crosstalk light signals reflected off the one or more interfaces and/or superficial layers which may lead to an erroneous signal, a low signal-to-noise ratio (SNR), or both (see at least abstract; [0035] of Shao). The rationale would have been to improve the accuracy of the optical detection/ measurement. Kuhn as modified by Shao discloses all the claimed limitations except the optical monitoring device is configured to selectively activate the first optical emitter or the first optical detector in response to a detected event. Cinbis teaches an implantable optical monitoring device is configured to selectively activate optical detector elements in response to a detected event (selectively activate detector elements based on detected intensity, [0084]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the device (Kuhn as modified by Shao) to incorporate the selectively activation function(s) as taught by Cinbis, since both devices are implantable optical sensing devices and one of ordinary skill on the art would have recognized that the selectively activation function(s) of detectors as taught by Cinbis facilitate conserving energy (see at least [0084] of Cinbis). The rationale would have been to conserve energy using intensity-based selectively activation functions. In regard to claim 3, Kuhn as modified by Shao and Cinbis discloses the first optical detector comprises an angularly selective filter (Figs. 4A-4F and 5A-5B and associated descriptions of Shao). In regard to claim 4, Kuhn as modified by Shao and Cinbis discloses the angularly selective filter comprises a plurality of angled members, a grating optical filter, an alternating layer filter, a lens, a mirror, or a collimator (angled members, alternating layer filter, a lens, and/or a collimator, Figs. 4A-4F and 5A-5B and associated descriptions of Shao). In regard to claim 5, Kuhn as modified by Shao and Cinbis discloses the angularly selective filter is configured to selectively transmit incident light at a first incident angle or a first range of incident angles and selectively block incident light at a second incident angle or second range of incident angles (different acceptance angles, Figs. 4A-4F and 5A-5B and associated descriptions of Shao). In regard to claim 6, Kuhn as modified by Shao and Cinbis discloses the plurality of angled members comprise an angle of from 5 degrees to 75 degrees relative to a surface normal of the angularly selective filter (Fig. 4C and associated descriptions of Shao). In regard to claim 7, Kuhn as modified by Shao and Cinbis discloses the first optical detector is configured to detect incident light having a first incident angle of from -75 degrees to +75 degrees relative to the surface normal (different acceptance angles, Figs. 4A-4F and 5A-5B and associated descriptions of Shao). In regard to claim 8, Kuhn as modified by Shao and Cinbis discloses the emitted light from the first optical emitter propagates through a lung tissue from 1 cm to 5 cm in depth as measured from a surface of the optical monitoring device (lung, [0026]; Fig. 2C and associated descriptions; [0043] of Kuhn; Similar to claim 1 above, when the device is integrated with a pacemaker/ ICD or implanted near the lung in the patient, it is inherent that some of the emitted light would propagates through a lung tissue at a depth of at least 1 cm to 5 cm). In regard to claim 9, Kuhn as modified by Shao and Cinbis discloses the first optical emitter and the first optical detector are spaced along a planar surface of the optical monitoring device of from 1 cm to 10 cm apart (according to the relative dimensions between the separation distances of the optical elements in the implantable sensors 12 and 30 and the relative dimension of the patient and/or the pacemaker/ ICD illustrated in Fig. 1, it is inherent that the separation distance, Fig. 2C and associated descriptions; [0043] of Kuhn, would be recognized in the range of 1cm to 10cm). If not inherent, Kuhn further discloses the sensor 30 can be implanted near the lung for monitor a desired tissue volume, [0026]; and Fig. 2C and [0043] requires proper separations between the first/ second emitters and the light detector ([0043]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to try different separation distances and associated sizes of the sensor for lung detection, including between 1cm to 10cm, through investigations/ experiments in order to find the optimal separation distance(s) and associated examining depths for desired lung tissue detections. The rationale would have been “obvious to try”, see KSR International Co. v. Teleflex Inc., 550 USPQ2d 398, 421(2007). In regard to claim 21, Kuhn as modified by Shao and Cinbis discloses the physiological parameter is selected from the group consisting of an oxygenation status of lung tissue, a pulmonary congestion status, a temperature, and a cardiogenetic airway modulation status (O2Sat, referring to claims 1 and 8-9 above; lung, [0026] of Kuhn). In regard to claim 24, Kuhn as modified by Shao and Cinbis discloses the optical monitoring device is further configured to deliver or suggest a therapy to a patient in response to a detected physiological parameter ([0020-0021]; [0057-0058] of Kuhn). In regard to claim 26, Kuhn as modified by Shao and Cinbis discloses the first optical emitter is disposed at least 6 cm away from the first optical detector (different separation distances and size of the sensor for lung detection, referring to claims 1 and 9 above) In regard to claim 27, Kuhn as modified by Shao and Cinbis discloses the emitted light from the first optical emitter propagates through a lung tissue at a depth of at least 3 cm as measured from a surface of the optical monitoring device and back to the first optical detector (referring to claims 1, 9 and 26 above; It is also noted that some of the emitted light (different wavelengths and types of light source of the first emitter) would propagate through the lung tissue at a depth of at least 3 cm as measured from a surface of the optical monitoring device and back to the first optical detector, [0043] and [0045]; lung, [0026] of Kuhn). Claim 22 is rejected under 35 U.S.C. 103 as being unpatentable over the combination of Kuhn, Shao and Cinbis as applied to claims 1, 3-9, 21, 24, and 26-27 above, and further in view of Nabutovsky et al. (USPN 8,175,668 – cited in previous action). In regard to claim 22, Kuhn as modified by Shao and Cinbis discloses the first emitter and the light detector comprises windows (Fig. 2C and associated descriptions; [0043] of Kuhn; referring to claim 1 above) but does not specifically disclose an optical barrier disposed between the first optical emitter and the first optical detector to prevent a direct path for light from the first optical emitter to the first optical detector Nabutovsky teaches an implantable optical device for oxygen detection (Fig. 1A and associated descriptions) comprises a first light emitter (elements 102/104/106, Fig. 1A and associated descriptions) and a second light emitter (element 108, Fig. 1A and associated descriptions) and a light detector (element 114, Fig. 1A and associated descriptions), wherein an optical barrier is disposed between the first optical emitter and the first optical detector to prevent a direct path for light from the first optical emitter to the first optical detector (element 122, Fig. 1A and associated descriptions; Col 3 line 61 – Col 4 line 10). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the device (Kuhn as modified by Shao and Cinbis) to incorporate the optical barrier between the emitter and detector as taught by Nabutovsky, since both devices are implantable optical systems for oxygen detection and one of ordinary skill in the art would have recognized that a barrier can be disposed between the emitter and detector to prevent light from traveling directly to the light sensor without interacting with the tissue (see Nabutovsky). The rationale would have been to reduce noise or unwanted signals and improve the optical measurements. Allowable Subject Matter Claims 25 and 29-30 are allowed. The following is an examiner’s statement of reasons for allowance: The prior art of record does not teach or suggest “a directional emission filter disposed on a surface of the first optical emitter….wherein the directional emission filter is configured to direct the emitted light from the first optical emitter with a maximum intensity in a direction along a vector oriented away from the first optical detector”, in combination with the other claimed elements/ steps. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.” Claim 28 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: The prior art of record does not teach or suggest “the detected event comprising any of abnormal heart rhythm, abnormal respiration pattern, high temperature, and low oxygenation” in combination with the other claimed elements/ steps. Response to Arguments Applicant’s amendment and argument with respect to claim 1 filed on 06/18/2026 have been fully considered but they are deemed to be moot in views of the new grounds of rejection. Applicant’s arguments, see page 7 of Remarks, filed on 06/18/2026, with respect to claims 8 and 27 have been fully considered and are persuasive. The 35 USC 112(b) rejections of claims 8 and 27 has been withdrawn. Upon further consideration, the Double Patenting rejection of claims 1, 8-9 and 25 is hereby withdrawn. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHU CHUAN LIU whose telephone number is (571)270-5507. The examiner can normally be reached M-Th (6am-6pm). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Robertson can be reached at (571) 272-5001. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHU CHUAN LIU/ Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Show 1 earlier event
Jul 24, 2025
Non-Final Rejection mailed — §103
Oct 22, 2025
Response Filed
Nov 20, 2025
Final Rejection mailed — §103
Feb 19, 2026
Request for Continued Examination
Mar 12, 2026
Response after Non-Final Action
Mar 19, 2026
Non-Final Rejection mailed — §103
Jun 18, 2026
Response Filed
Jul 16, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12697050
Apparatus and Method for Analyte Measurement with Improved Coupling of Excitation Radiation into Material Including Said Analyte
3y 8m to grant Granted Aug 04, 2026
Patent 12685519
ORAL FLUID COLLECTION DEVICE
2y 9m to grant Granted Jul 21, 2026
Patent 12661036
DETECTION DEVICE
3y 6m to grant Granted Jun 23, 2026
Patent 12661037
OPTICAL MODULE
2y 9m to grant Granted Jun 23, 2026
Patent 12653461
WEARABLE DEVICE AND METHODS OF MANUFACTURING
2y 7m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
71%
Grant Probability
86%
With Interview (+14.2%)
3y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 776 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month